Glutamate-related excitoxicity neuroprotection with memantine, an uncompetitive antagonist of nmda-glutamate receptor, in Alzheimer's disease and vascular dementia;Neuroprotección con memantina (antagonista no competitivo del receptor NMDA-glutamato) frente a la excitotoxicidad asociada al glutamato en la enfermedad de Alzheimer y en la demencia vascular

Revista de Neurologia

Volumn 42, Issue 10, 2006, Pages 607-616

  Tanovic A ^a   Alfaro, Vicente ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Alzheimer's disease; Memantine; NMDA receptor; Uncompetitive antagonist; Vascular dementia

Indexed keywords

AMYLOID BETA PROTEIN; BETA AMYLOID PEPTIDE[1-42]; CALCIUM; DONEPEZIL; GALANTAMINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; IDEBENONE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; RIVASTIGMINE; TACRINE; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; EXCITOTOXICITY; FUNCTIONAL DISEASE; HUMAN; LEARNING; MEMORY; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; MULTIINFARCT DEMENTIA; NEUROPROTECTION; NEUROTRANSMISSION; OXIDATIVE STRESS; REVIEW; SYMPTOMATOLOGY; CHEMICAL STRUCTURE; METABOLISM; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; CLINICAL TRIALS; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; MEMANTINE; MOLECULAR STRUCTURE; NEUROPROTECTIVE AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 33750095167     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4210.2005252     Document Type: Review

References (41)

1. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer's 1907 paper, 'Uber eine eigenartige Erkankung der Hirnrinde'. Clin Anat 1995; 8: 429-31.
2. Wang HX, Karp A, Winblad B, Fratiglioni L. Late-life engagement in social and leisure activities is associated with a decreased risk of dementia: a longitudinal study from the Kungsholmen project. Am J Epidemiol 2002; 155: 1081-7.
3. Butterfield DA, Pocernich CB. The glutamatergic system and Alzheimer's disease: therapeutic implications. CNS Drugs 2003; 17: 641-52.
4. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002; 298: 789-91.
5. Davies CA, Mann DM, Sumpter PQ, Yates PO. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci 1987; 78: 151-64.
6. Masters CL, Beyreuther K. Molecular neuropathology of Alzheimer's disease. Arzneimittelforschung 1995; 45: 410-2.
7. Selkoe DJ. Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem 1996; 271: 18295-8.
8. Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 1993; 10: 243-54.
9. Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry 2003; 18 (Suppl 1): S23-32.
10. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993; 361: 31-9.
11. Greenamyre JT, Young AB. Excitatory amino acids and Alzheimer's disease. Neurobiol Aging 1989; 10: 593-602.
12. Zoia C, Cogliati T, Tagliabue E, Cavaletti G, Sala G, Galimbert G, et al. Glutamate transporters in platelets: EAAT1 decrease in aging and in Alzheimer's disease. Neurobiol Aging 2004; 25: 149-57.
13. Butterfield DA, Hensley K, Cole P, Subramaniam R, Aksenov M, Aksenova M, et al. Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer's disease. J Neurochem 1997; 68: 2451-7.
14. Olney JW, Wozniak DF, Farber NB. Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies. Arch Neurol 1997; 54: 1234-40.
15. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev 2003; 9: 275-308.
16. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 1999; 38: 735-67.
17. Miguel-Hidalgo JJ, Álvarez XA, Cacabelos R, Quack G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid (1-40). Brain Res 2002; 958: 210-21.
18. Blanpied TA, Boeckman FA, Aizenman E, Johnson JW. Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol 1997; 77: 309-23.
19. Bormann J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 1989; 166: 591-2.
20. Parsons CG, Panchenko VA, Pinchenko VO, Tsyndrenko AY, Krishtal OA. Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur J Neurosci 1996; 8: 446-54.
21. Parsons CG, Gruner R, Rozental J, Millar J, Lodge D. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 1993; 32: 1337-50.
22. Wenk GL, Zajaczkowski W, Danysz W. Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B. Behav Brain Res 1997; 83: 129-33.
23. Rao VL, Dogan A, Todd KG, Bowen KK, Dempsey RJ. Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats. Brain Res 2001; 911: 96-100.
24. Marvanova M, Lakso M, Pirhonen J, Nawa H, Wong G, Castren E. The neuroprotective agent memantine induces brain-derived neurotrophic factor and TrkB receptor expression in rat brain. Mol Cell Neurosci 2001; 18: 247-58.
25. Schugens MM, Egerter R, Daum I, Schepelmann K, Klockgether T, Loschmann PA. The NMDA antagonist memantine impairs classical eyeblink conditioning in humans. Neurosci Lett 1997; 224: 57-60.
26. Rammsayer TH. Effects of pharmacologically induced changes in NMDA-receptor activity on long-term memory in humans. Learn Mem 2001; 8: 20.
27. Schulz H, Jobert M, Coppola R, Herrmann WM, Pantev M. The use of diurnal vigilance changes in the EEG to verify vigilance-enhancing effects of memantine in a clinical pharmacological study. Neuropsychobiology 1996; 33: 32-40.
28. Jain KK. Evaluation of memantine for neuroprotection in dementia. Expert Opin Investig Drugs 2000; 9: 1397-406.
29. Lundbeck H. Summary of product characteristics. Ebixa (memantine hydrochloride). Valby: Lundbeck A/S; 2002. p. 1-13.
30. Forest Pharmaceuticals. Summary of product characteristics. Namenda TM (memantine hydrochloride). 2003.
31. Kornhuber J, Quack G. Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 1995; 195: 137-9.
32. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-41.
33. Ferris SH, Schmidt F, Doody R. Long-term treatment with the NMDA antagonist memantine: results of a 24-week, open-label extension study in advanced Alzheimer's disease. Annual Meeting of the American College of Neuropsychopharmacology. Waaikoloa Village, Hawaii; 9-13 de diciembre de 2001.
34. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Jama 2004; 291: 317-24.
35. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14: 135-46.
36. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33: 1834-9.
37. Wilcock G, Mobius HJ, Stoffler A, MMM500 group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002; 17: 297-305.
38. Ditzler K. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Arzneimittelforschung 1991; 41: 773-80.
39. Hartmann S, Mobius HJ. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol 2003; 18: 81-5.
40. Jarvis B, Figgitt DP. Memantine. Drugs Aging 2003; 20: 465-78.
41. Bisaga A, Evans SM. Acute effects of memantine in combination with alcohol in moderate drinkers. Psychopharmacology (Berl) 2004; 172: 16-24.